Trial Profile
Evaluation of Safety, Tolerability and Immunogenicity of Adjuvanted Candidate Vaccines Against Pandemic Influenza A (H1N1)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Influenza A virus vaccine-H1N1 (Primary) ; Aluminium hydroxide; Monophosphoryl lipid A
- Indications Influenza A virus H1N1 subtype
- Focus Pharmacodynamics
- 05 May 2011 Actual end date (Mar 2011) added as reported by ClinicalTrials.gov.
- 05 May 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 06 Jul 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.